| Literature DB >> 20615380 |
Anja Taubert1, Klaus Wimmers, Siriluck Ponsuksili, Cristina Arce Jimenez, Horst Zahner, Carlos Hermosilla.
Abstract
Within its life cycle Eimeria bovis undergoes a long lasting intracellular development into large macromeronts in endothelial cells. Since little is known about the molecular basis of E. bovis-triggered host cell regulation we applied a microarray-based approach to define transcript variation in bovine endothelial cells early after sporozoite invasion (4 h post inoculation (p.i.)), during trophozoite establishment (4 days p.i.), during early parasite proliferation (8 days p.i.) and towards macromeront maturation (14 days p.i.). E. bovis infection led to significant changes in the abundance of many host cell gene transcripts. As infection progressed, the number of regulated genes increased such that 12, 45, 175 and 1184 sequences were modulated at 4 h, 4, 8 and 14 days p.i., respectively. These genes significantly interfered with several host cell functions, networks and canonical pathways, especially those involved in cellular development, cell cycle, cell death, immune response and metabolism. The correlation between stage of infection and the number of regulated genes involved in different aspects of metabolism suggest parasite-derived exploitation of host cell nutrients. The modulation of genes involved in cell cycle arrest and host cell apoptosis corresponds to morphological in vitro findings and underline the importance of these aspects for parasite survival. Nevertheless, the increasing numbers of modulated transcripts associated with immune responses also demonstrate the defensive capacity of the endothelial host cell. Overall, this work reveals a panel of novel candidate genes involved in E. bovis-triggered host cell modulation, providing a valuable tool for future work on this topic. © INRA, EDP Sciences, 2010.Entities:
Mesh:
Year: 2010 PMID: 20615380 PMCID: PMC2920636 DOI: 10.1051/vetres/2010041
Source DB: PubMed Journal: Vet Res ISSN: 0928-4249 Impact factor: 3.683
Host cell gene transcription significantly modulated by E. bovis infection (selected).
| Functional class | Symbol | Gene | Fold change in transcription | |||
|---|---|---|---|---|---|---|
| 4 h | 4 d | 8 d | 14 d | |||
| Transcription/Translation | FOS | v-fos FBJ murine osteosarcoma viral oncogene homolog | 2.45 | 1.69 | 1.97 | 1.82 |
| KLF4 | Kruppel-like factor 4 | – | – | 2.21 | 2.14 | |
| KLF5 | Kruppel-like factor 5 | – | – | 1.51 | 2.60 | |
| NR2F1 | Nuclear receptor subfamily 2, gr F, member 1 | – | – | −1.69 | −2.55 | |
| PRICKLE1 | Prickle homolog 1 | – | – | 2.05 | 2.97 | |
| FHL2 | Four and a half LIM domains 2 | – | – | 1.98 | 3.88 | |
| CAMTA1 | Calmodulin binding transcription activator 1 | – | – | – | −2.74 | |
| CRYM | Crystallin, mu | – | – | – | 4.12 | |
| EIF4E | Eukaryotic translation initiation factor 4E | – | – | 2.12 | 1.65 | |
| MRPS6 | Mitochondrial ribosomal protein S6 | – | – | – | 3.46 | |
| PPARG | Peroxisome proliferator-activated receptor gamma | – | – | – | −2.77 | |
| Signal transduction | RND1 | Rho family GTPase 1 | – | – | 2.28 | 2.34 |
| SOCS1 | Suppressor of cytokine signaling | – | – | 2.21 | 3.24 | |
| DKK3 | Dickkopf homolog 3 | – | – | 1.73 | 3.96 | |
| STK38L | Serine/threonine kinase 38 like | – | – | 1.69 | 3.05 | |
| PPP1R1B | Protein phosphatase 1, regulatory subunit 1B | – | – | −2.14 | −5.31 | |
| PTGER4 | prostaglandin E receptor 4 | – | – | −1.76 | −5.31 | |
| RASD1 | dexamethasone-induced ras-related protein 1 | – | – | −1.61 | −3.05 | |
| FGL1 | Fibrinogen-like 1 | – | – | – | −4.49 | |
| GPR116 | G protein-coupled receptor 116 | – | – | – | −2.65 | |
| LGR4 | Leucine-rich repeat-containing G protein-coupled receptor 4 | – | – | – | −2.65 | |
| ARHGEF11 | Rho guanine nucleotide exchange factor 11 | – | – | – | 2.98 | |
| APLP2 | Amyloid beta (A4) precursor-like protein 2 | – | – | – | 2.60 | |
| PTPN1 | protein tyrosine phosphatase, non-receptor type 1 | – | – | – | 4.22 | |
| RAB26 | Ras-related oncogene protein | – | – | – | 2.77 | |
| RASGEF1B | RasGEF domain family, member 1B | – | – | – | −2.65 | |
| RUVBL1 | RuvB-like protein 1 | – | – | – | 2.56 | |
| CHP | Calcineurin homologous protein | – | – | – | 2.77 | |
| SPARCL1 | SPARC-like 1 | – | – | – | −2.65 | |
| Nuclear protein | HIST2H2BE | Histone cluster 2, H2BE | – | 2.13 | 2.13 | 2.82 |
| SNRNP25 | Small nuclear ribonucleoprotein 25kDa | – | – | – | 2.71 | |
| Metabolism | ||||||
| CYP51 | Cytochrome P450, family 51 | – | – | – | 3.59 | |
| CH25H | Cholesterol 25-hydroxylase | – | – | 2.26 | 3.14 | |
| OLR1 | Oxidized low density lipoprotein receptor 1 | – | – | 2.14 | 2.72 | |
| ELOVL5 | Elongation of long chain fatty acids member 5 | – | – | 1.73 | 2.64 | |
| ELOVL6 | Elongation of long chain fatty acids member 6 | – | – | – | 2.85 | |
| NAMPT | Nicotinamide phosphoribosyl-transferase | – | – | 1.50 | 2.60 | |
| ACOT7 | Acyl-Coenzyme A thioesterase 7 | – | – | 1.57 | 4.46 | |
| IDI1 | Isopentenyl-diphosphate delta isomerase 1 | – | – | – | 7.74 | |
| SCD | Stearoyl-Coenzyme A desaturase | – | – | – | 5.26 | |
| HMGCS1 | Hydroxy-methylglutaryl-Coenzyme A synthase 1 | – | – | – | 3.51 | |
| ACAT2 | Acetyl-Coenzyme A acetyltransferase 2 | – | – | – | 2.99 | |
| FASN | Fatty acid synthase | – | – | – | 2.68 | |
| FADS1 | Fatty acid desaturase 1 | – | – | – | 3.42 | |
| FDPS | Farnesyl diphosphate synthase | – | – | – | 2.68 | |
| FABP | Fatty acid binding protein 3 | – | – | – | 3.60 | |
| PLD1 | Phospholipase D1 | – | – | – | −2.66 | |
| NSDHL | NAD(P) dependent steroid dehydrogenase-like | – | – | – | 2.69 | |
| ACER3 | Alkaline ceramidase 3 | – | – | – | 2.62 | |
| GALT | Galactose-1-phosphate uridylyltransferase | – | – | 1.53 | 3.17 | |
| STBD1 | Starch binding domain 1 | – | – | 2.11 | 4.35 | |
| CHPF | Chondroitin polymerizing factor | – | – | – | 4.80 | |
| SULF2 | Sulfatase 2 | – | – | – | 3.20 | |
| UGGT2 | UDP-glucose glycoprotein glucosyltransferase 2 | – | – | – | 3.17 | |
| EXT1 | Exostoses (multiple) 1 | – | – | – | 2.51 | |
| MTHFD1L | Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like | – | 1.63 | 2.87 | 10.78 | |
| MTHFD2 | Methenyltetrahydrofolate cyclohydrolase | – | – | 2.05 | 3.06 | |
| CYP1A1 | Cytochrom p450 1A1 | 6.35 | – | – | – | |
| PSAT1 | Phosphoserine aminotransferase 1 | – | −1.52 | 1.93 | 2.96 | |
| PSPH | Phosphoserine phosphatase | – | −1.50 | 1.69 | 3.33 | |
| GOT1 | Glutamic-oxaloacetic transaminase 1 | – | – | – | 3.79 | |
| GPT2 | Glutamic pyruvate transaminase 2 | – | – | – | 2.89 | |
| WDYHV1 | WDYHV motif containing 1 | – | – | – | 2.93 | |
| UPP1 | Uridine phosphorylase 1 | – | – | 2.24 | 2.94 | |
| CTPS | Cytidine 5′-triphosphate synthetase | – | – | – | 3.63 | |
| RRM2 | Ribonucleotide reductase M2 polypeptide | – | – | 1.83 | 6.70 | |
| ME1 | Malic enzyme 1, NADP(+)-dependent, cytosolic | – | – | – | 3.19 | |
| MDH1 | Malate dehydrogenase 1 | – | – | – | 2.53 | |
| KCNK1 | Potassium channel, subfamily K, member 1 | – | 1.85 | 2.37 | 3.22 | |
| TMEM98 | Transmembrane protein 98 | – | 1.67 | 2.33 | 2.74 | |
| SFXN1 | Sideroflexin 1 | – | – | – | 3.78 | |
| Transport | SLC25A33 | Solute carrier family 25, member 33 | – | – | 1.62 | 2.84 |
| SLC31A1 | Solute carrier family 31, member 1 | – | – | 1.91 | 6.50 | |
| SLC25A4 | Solute carrier family 25, member 4 | – | – | – | 3.33 | |
| SLC2A3 | Solute carrier family 2, member 3 | – | – | – | 3.35 | |
| TINAGL1 | Tubulointerstitial nephritis antigen-like 1 | – | – | – | 3.51 | |
| TFRC | Transferrin receptor | −1.54 | – | – | 2.51 | |
| Cell cycle | CCND2 | Cyclin D2 | – | – | 2.38 | 5.42 |
| CCNE1 | Cyclin E1 | – | – | 2.05 | 4.76 | |
| PMP22 | Peripheral myelin protein 22 | – | – | 2.03 | 3.51 | |
| S100A4 | S100 calcium binding protein A4 | – | – | 2.05 | 2.34 | |
| S100A2 | S100 calcium binding protein A2 | – | −1.53 | – | 2.55 | |
| PTTG1 | Pituitary tumor-transforming protein 1 | 2.51 | ||||
| Cell growth/proliferation | TIMP2 | Tissue inhibitor of metalloproteinase 2 | – | – | 2.31 | 7.96 |
| CYR61 | Cysteine-rich, angiogenic inducer, 61 | – | – | 2.48 | 2.89 | |
| EGR1 | Early growth response 1 | 2.37 | – | 2.65 | 1.84 | |
| FGF1 | Fibroblast growth factor 1, acidic | – | 2.13 | 2.25 | 2.77 | |
| VEGFA | Vascular endothelial growth factor A | – | – | 2.46 | – | |
| VEGFC | Vascular endothelial growth factor C | – | – | 2.07 | 22.23 | |
| CSRP2 | Cysteine and glycine-rich protein 2 | – | – | 1.72 | 11.25 | |
| SERPINE2 | Serpin peptidase Inhibitor, clade E member 2 | – | – | – | 2.86 | |
| CD320 | CD320 molecule | – | – | – | 2.85 | |
| Cell structure | COL1A2 | Collagen, type I, alpha 2 | – | −2.57 | – | −2.22 |
| FGD4 | FYVE, RhoGEF and PH domain containing 4 | – | – | −1.51 | −3.13 | |
| PALLD | Palladin, cytoskeletal associated protein | – | – | – | 3.64 | |
| MAP1B | Microtubule-associated protein 1B | – | – | – | 3.23 | |
| TUBB | Tubulin, beta | – | – | – | 2.90 | |
| Cell adhesion | SELP | Selectin P | – | – | 2.29 | 7.23 |
| VCAM1 | Vascular cell adhesion molecule 1 | – | – | 2.18 | – | |
| THBS | Thrombospondin 1 | – | −1.67 | 2.05 | 1.52 | |
| THBS2 | Thrombospondin 2 | – | −1.63 | 2.13 | 1.62 | |
| LGALS1 | Lectin, galactoside-binding, soluble, 1 | – | – | 1.71 | 11.61 | |
| TPBG | Trophoblast glycoprotein | – | – | 1.58 | 3.60 | |
| CLDN16 | Claudin 16 | – | – | – | −2.70 | |
| PARVB | Parvin, beta | – | – | – | 2.71 | |
| LAMA3 | Laminin, alpha 3 | – | – | – | −2.61 | |
| Stress response | USP2 | Ubiquitin specific peptidase 2 | – | – | – | −3.92 |
| SERPINH1 | Serpin peptidase Inhibitor, clade H member 1 | – | – | 1.51 | 3.03 | |
| Apoptosis | DRAM | DNA-damage regulated autophagy modulator 1 | – | – | −1.62 | −3.20 |
| CYCS | Cytochrome c, somatic | – | – | – | 2.90 | |
| TIMP4 | Tissue inhibitor of metalloproteinase 4 | – | – | −1.65 | −3.28 | |
| Immune response | IFI30 | Interferon-gamma-inducible protein 30 | – | – | 1.66 | 24.16 |
| IL8 | Interleukin-8 | – | – | 3.75 | – | |
| CXCL5 | Chemokine (C-X-C motif) ligand 5 | – | – | 3.63 | – | |
| CXCL1 | Chemokine (C-X-C motif) ligand 1 | – | – | 2.52 | – | |
| CCL26 | Chemokine (C-C motif) ligand 26 | – | – | 2.11 | 1.63 | |
| CXCR4 | Chemokine (C-X-C motif) receptor 4 | – | – | – | −2.71 | |
| SERPINE1 | plasminogen activator inhibitor-1 | – | −1.53 | 3.19 | – | |
| PLAU | Plasminogen activator, urokinase | – | 1.90 | 2.64 | 1.88 | |
| PLAT | plasminogen activator, tissue | – | – | 1.54 | 8.77 | |
| C3 | Complement component 3 | – | – | 2.54 | 2.60 | |
| CFB | Complement factor B | – | – | 2.78 | 2.50 | |
| C1QBP | Complement component 1, q subcomponent binding protein | – | – | – | 2.56 | |
| CD200 | CD200 molecule | – | – | – | 6.51 | |
| TAP1 | Transporter 1, ATP-binding cassette, sub-family B | 3.49 | ||||
| Unknown function | TM4SF18 | Transmembrane 4 L six family member 1 | – | – | – | 3.28 |
| SYNGR2 | Synaptogyrin 2 | – | – | 1.61 | 5.93 | |
| DBNDD2 | Dysbindin (dystrobrevin binding protein 1) domain containing 2 | – | – | 1.79 | 3.26 | |
| FIBIN | Fin bud initiation factor homolog | – | – | 1.61 | −3.09 | |
| GLIPR2 | GLI pathogenesis-related 2 | – | – | 2.06 | 3.00 | |
| B9D1 | B9 protein domain 1 | 1.55 | 2.75 | |||
| GPM6B | Glycoprotein M6B | – | – | – | −3.17 | |
| PALD | KIAA1274 | – | – | – | −2.89 | |
| HIGD1D | HIG hypoxia inducible domain family, member 1D | – | – | – | 2.62 | |
| SELM | Selenoprotein M | – | – | – | 2.85 | |
Only genes with ≥ 2-fold (4 h, 4 and 8 d) and ≥ 2.5-fold (14 d) changes in at least one tested time point versus non-infected controls are considered.
Canonical pathways significantly over-represented by E. bovis-regulated genes in infected bovine endothelial host cells (p ≤ 0.05).
| Canonical Pathway | p.i. | Molecules |
|---|---|---|
| Aryl Hydrocarbon Receptor Signaling | 4 h | FOS, CYP1A1 |
| 8 d | NR2F1, MYC, FOS, CCNE1, CCND2, TGFB2 | |
| 14 d | GSTM1, MGST1, CCNE2, GSTP1, IL6, MYC, NR2F1, | |
| HMGB1 Signaling | 4 d | FOS, SERPINE1 |
| 8 d | IL8, FOS, VCAM1, ICAM1, SERPINE1, PLAT | |
| 14 d | KAT2B, FOS, JUN, MAPK14, SP1, CDC42, | |
| HGF Signaling | 14 d | MAP3K11, CDC42, PLCG1, IL6, FOS, JUN, |
| IGF-1 Signaling | 4 d | FOS, IGFBP5, NEDD4 |
| 14 d | FOS, YWHAG, JUN, NOV, YWHAH, MRAS, | |
| ERK5 Signaling | 4 h | FOS |
| 14 d | MYC, FOS, YWHAG, YWHAH, GAB1, MRAS, | |
| NRF2-mediated Oxidative Stress Response | 14 d | AKR7A2, GSTM1, GSTP1, USP14, MGST1, DNAJC3, |
| Protein Ubiquitination Pathway | 14 d | PSMB9, UCHL3, USP14, PSMB5, PSMD7, PSMC4, |
| Acute Phase Response | 8 d | SOCS1, FOS, SOD2, C1S, NOLC1, CFB, SERPINE1 |
| Leukocyte Extravasation Signaling | 8 d | TIMP4, VCAM1, ICAM1, EZR, TIMP2 |
| 14 d | TIMP3, CDC42, CXCR4, MMP16, PLCG1, RAPGEF3, | |
| IL-8 Signaling | 8 d | IL8, VCAM1, ICAM1, CCND2, CXCL1, VEGFC |
| Coagulation System | 4 d | PLAUR, PLAU, SERPINE1 |
| 8 d | PLAUR, PLAU, SERPINE1, PLAT | |
| Cell Cycle: G1/S Checkpoint Regulation | 8 d | MYC, CCNE1, CCND2, TGFB2 |
| 14 d | MYC, CCNE2, CCNE1, CCND3, HDAC3, CCND2, | |
| Cell Cycle: G2/M DNA Damage Regulation | 8 d | TOP2A, CCNB2, BRCA1 |
| 14 d | KAT2B, GADD45A, PTPMT1, CDKN1A, TOP2A, CCNB2 |
As generated by Ingenuity Pathway Analyses program.